The global poultry pharmaceuticals market is estimated to be valued at US$ 7.35 Billion in 2023 and is expected to exhibit a CAGR of 8.8% during the forecast period (2023-2030).
Analysts’ Views on Global Poultry Pharmaceuticals Market:
Increasing initiatives by government and animal welfare associations, the rising occurrence of zoonotic diseases, and the rise in demand for poultry-derived food products are contributing to the market growth. The number of zoonotic disease cases in poultry animals has risen significantly in recent years. The rising company activities in developing products and increasing product launches also contribute to the market growth. The rising company activities in developing vaccines for preventing poultry animals from infections and diseases are also contributing to the market growth.
Figure 1. Global Poultry Pharmaceuticals Market Share (%), By Product Type, 2023
To learn more about this report, request sample copy
Global Poultry Pharmaceuticals Market– Driver
Increasing consumption of chicken
Increasing consumption of chicken is expected to propel growth of the global poultry pharmaceuticals market over the forecast period. Poultry involves raising of birds like ducks, turkeys, chickens and geese for their eggs and meat at domestic or commercial level. Over the decades, the Global poultry pharmaceuticals market has undergone significant transformation, and the region has emerged as one of the major sectors of the economy. For instance,in July 2021, according to research presented at the 2021 Chicken Marketing Summit, Florida, U.S., 98% of consumers during a two week survey in the U.S. ate a chicken meal or snack purchased from a supermarket and 68% ate a chicken meal or snack from a food service establishment.
Significant growth of the poultry sector
Significant growth of the poultry sector is also expected to aid in growth of the market. For instance, according to a report in November 2022, by the U.S. Poultry and Egg Association, National Chicken Council, National Turkey Federation and United Egg Producers, the study breaks down poultry into three subcategories: chicken, turkey and eggs. The chicken industry provides 1,517,797 jobs, US$ 94.9 billion in wages, US $417 billion in economic activity and US$ 25.5 billion in government revenue repectively.
Figure 2. Global Poultry Pharmaceuticals Market Share (%), By Region, 2023
To learn more about this report, request sample copy
Global Poultry Pharmaceuticals Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global poultry pharmaceuticals market over the forecast period. North America is estimated to hold 38.3% of the market share. The growing prevalence of Zoonotic disease and infectious disease directly impacts on the increased demand for the global poultry pharmaceuticals market. For instance, on January 19, 2023, according to the World Health Organization, per year around, 35,172 human deaths and 21,476 human deaths occur due to Zoonotic in North America. The cases of patients suffering from polio in Asia Pacific are reducing because of increasing awareness regarding the prevention of polio and rabies among the population and free immunization camps, which are organized by the government for immunizing the population against infectious and zoonotic disease. Thus, North America is also projected to spur the global poultry pharmaceuticals market growth over the forecast period.
Global Poultry Pharmaceuticals Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global poultry pharmaceuticals market. For instance, according to an published in Elsevier Journal In April 2022, COVID-19 vaccine dose sparing to improve vaccine equity and pandemic preparedness. New vaccines had developed at an unprecedented pace. The development process had accelerated in multiple ways by running the different clinical testing phases in parallel, rolling reviews by the regulatory authorities, and starting large-scale production before regulatory approval is helpful for global poultry pharmaceutical market.
Poultry Pharmaceuticals Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: |
2022 |
Market Size in 2023: | US$ 7.35 Bn |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 8.8% | 2030 Value Projection: | US$ 13.23 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Bayer AG, Bimeda, Ceva Sante Animale, Elanco Animal Health (Eli Lilly and Company), Merck Animal Health, Merial Animal Health (Sanofi), Virbac, Boehringer Ingelheim, Zoetis, Inc., Pacific GeneTech, and Avivagen Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Poultry Pharmaceuticals Market Segmentation:
The global Poultry Pharmaceuticals market report is segmented into By Product Type, By Animal type, and By Region.
By Product Type, the global poultry pharmaceuticals market is segmented into Drugs (Vetrimoxin, Other Drug Products), Vaccines (Innovax, Nobilis, Poulvac, Other Vaccine Products), and Feed Additives (VIGOSINE, Amnovit, Other Feed Additives). Out of which, the Drugs (Vetrimoxin, Other Drug Products) segment is expected to dominate the poultry pharmaceuticals market during the forecast period and this is due to the increase in the prevalence of Zoonotic disease.
By Animal type, the global poultry pharmaceuticals market is segmented into Chicken, Turkey, Duck, Goose, and Others. Out of which, the chicken segment is expected to dominate the global poultry pharmaceuticals market during the forecast period and this is due to the increasing consumption of chicken.
Among all the segmentations, the animal type segment has the potential due to the increasing government initiatives to preventive vaccines this is expected to drive the growth of the segment over the forecast period. For instance, according to the United States Department of Agriculture, Foreign Agricultural Service, January 2023 report, with upward improvements for the U.K., Thailand, and Mexico, global chicken meat production for 2023 is estimated to be 102.9 million tons. Similarly, global chicken meat exports for 2023 were estimated to be 14.0 million tons. With the increasing chicken meat production, the need to opt for preventive vaccines to prevent diseases in poultry also increases, which is expected to help the segmental growth over the forecast period.
Global Poultry Pharmaceuticals Market Cross Sectional Analysis:
Rising incidence of Zoonotic disease in emerging economies is also expected to boost demand for poultry pharmaceuticals in the North America region. North America is expected to dominate the global poultry pharmaceuticals market over the forecast period, owing to factors such as the rising demand for poultry-derived food products and the rising occurrence of zoonotic diseases in the region. For instance, according to the United States Department of Agriculture, Foreign Agricultural Service, January 2023 report, chicken meat production in the U.S. increased from 20,391 in 2021 to 20,845 in 2022, and chicken meat production in Mexico increased from 3,815 in 2021 to 3,900 in 2022. With the increasing poultry production, the number of poultry affected by diseases is also expected to increase. To counter this, the farmers are expected for poultry healthcare, driving market growth over the forecast period.
Global Poultry Pharmaceuticals Market: Key Developments
In February 2021, Merck Animal Health is parent company of MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., is an American multinational pharmaceutical company announced the completion of its acquisition of PrognostiX Poultry Limited d/b/a Poultry Sense Ltd. from its founding shareholders. Poultry Sense Ltd. is an innovator in health and environmental monitoring solutions for the poultry industry.
In April 2022, Ceva Animal Health, is the animal health company in France, launched CEVAC IBird, a live attenuated freeze-dried vaccine, for the active immunization of chickens against the variant strain of avian infectious bronchitis virus, containing strain 1/96, in India.
In August 2022, Bimeda, Inc., a veterinary pharmaceutical and animal health specialist company in Kenya, announced its latest significant investment, via the acquisition of South Africa's leading animal health distributor, Afrivet Southern Africa Proprietary Limited. the acquisition provide Bimeda with the largest footprint of any animal health company on the African continent.
In October 2020, Boehringer Ingelheim Animal Health, a pharmaceutical company in Mumbai, launched an innovative, first-of-its-kind vaccine in the U.S. to protect poultry from three diseases. VAXXITEK HVT+IBD+ILT is the first vaccine to offer protection in one shot from Infectious Laryngotracheitis, Marek's Disease and Infectious Bursal Disease (classic and variant types).
On February 14, 2023, Boehringer Ingelheim Animal Health USA Inc., announced they have entered a strategic collaboration with Alizent, a subsidiary of Air Liquide, to implement an innovative cold chain tracking solution to enhance poultry vaccine supply chain management. Some poultry vaccines are frozen at -200°C (-328°F) and shipped in containers, known as Dewars, filled with liquid nitrogen (LN2) to maintain the cold temperature during transit and protect the efficacy of live cells inside the vaccines. The collaboration taps into the growing interconnectivity of the Internet of Things (IoT) by using Alizent’s SmartDewar IoT platform to track Dewars housing liquid nitrogen and cryogenic samples, such as poultry vaccines.
Global Poultry Pharmaceuticals Market: Key Trends
Resesarch and developemnet in poultry nutrition
Resesarch and developemnet in poultry nutrition is expected to witness significant growth due to the increasing number of government initiatives for gene marker for chicken and routine immunization programs. For instance, in May 2020, researchers from Veterinary Research Institute, Czech Republic, reported that the TGFβ3 gene could used as a candidate gene marker for chicken growth traits.
Global Poultry Pharmaceuticals Market: Restraint
Product recall by regulatory bodies
Product recall by regulatory bodies is expected to hamper the growth of the global inactivated vaccines market. Low product exclusivity, generic competition, and stringent regulations are expected to hinder growth of the global poultry pharmaceuticals market. For instance, In June 2021, Manna Pro Products LLC manufactures and markets animal feed products Issued Limited Voluntary Recall of Flock Party Quack Snacks Sold in the United States Because of Possible Health Risk Due to Potential Salmonella Contamination.
Key players are focusing on quality and efficacy of the product.
Global Poultry Pharmaceuticals Market - Key Players
Major players operating in the global poultry pharmaceuticals market include Bayer AG, Bimeda , Ceva Sante Animale, Elanco Animal Health (Eli Lilly and Company), Merck Animal Health, Merial Animal Health (Sanofi), Virbac, Boehringer Ingelheim, Zoetis, Inc., Pacific GeneTech, and Avivagen Inc.
Defination: Poultry pharmaceuticals comprise vaccines, feed additive medication, and drugs such as parasiticides, and specialized products used to manage reproductive, metabolic or infectious diseases. Poultry medication is used to treat and prevent some illnesses that have an impact on the health and productivity of the birds.
Share
About Author
Vipul Patil
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients